Gilead Sciences, Inc. (GILD)

Nasdaq · Foster City, California, USA · Founded 1987 · CEO Daniel O'Day

Valuation summary

$105.10 fair value versus $166.53 in the market, a difference of -36.9%. Rated Sell.

Fair value per share$105.10
Current share price$166.53
Upside / downside-36.9%
Bear case$69.23
Bull case$155.20
Discount rate (WACC)8.9%
Terminal growth2.20%
Market capitalisation$206B
EV / Sales7.3x

About Gilead Sciences, Inc.

Founded in 1987 by Michael Riordan, a 29-year-old physician. Daniel O'Day has been CEO since 2019. Gilead built the modern HIV treatment franchise — Biktarvy is the most prescribed HIV regimen in the world — and later transformed hepatitis C from a chronic condition into a curable one. That cure destroyed its own market, an unusual case of clinical success undermining commercial value. The company has since spent heavily to build an oncology franchise, with mixed results.

Investment case

  • Biktarvy has dominant share in HIV treatment with high barriers and very strong margins.
  • Lenacapavir, a long-acting injectable, could substantially expand the HIV prevention market.
  • Free cash flow generation is exceptional and supports a large dividend.

Key risks

  • Heavy dependence on a single therapeutic area — around two thirds of revenue is HIV.
  • The oncology expansion, particularly Trodelvy and the Immunomedics acquisition, has disappointed relative to its cost.
  • HIV patent exclusivity begins to erode in the 2030s and the replacement is not yet visible.

Recent developments

Revenue by segment

HIV68%
Oncology12%
Liver Disease11%
Other9%

Five-year forecast

RevenueFree cash flow
Year 1$32.7B$8.6B
Year 2$34.9B$8.9B
Year 3$37.2B$9.2B
Year 4$39.6B$9.6B
Year 5$42.2B$9.9B

What the street says

Viewed as a cash-generative franchise with a concentration problem, but sentiment has improved, with the shares up nearly 20% in 2026 by late August. Lenacapavir uptake in prevention and new combinations such as Bixlenvo, approved in August 2026, are the main swing factors.

Comparable companies: NVO · DHR · AMGN · NVS · TMO · AZN · VRTX · ABBV

Open the interactive model, price chart and sensitivity grid →